Mantle Cell Lymphoma

📋 Key Information Summary

📋

Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma driven by the t(11;14)(q13;q32) translocation causing cyclin D1 (CCND1) overexpression; accounts for 3–10 % of all NHL in Australia.
Median age at diagnosis 65–70 years; male-to-female ratio approximately 3:1. Most patients present with Ann Arbor Stage III–IV disease with widespread lymphadenopathy and extranodal involvement.
SOX11 positivity by immunohistochemistry is present in ~90 % of conventional MCL and helps distinguish MCL from other CD5-positive B-cell lymphomas, particularly when cyclin D1 is equivocal.
Blastoid and pleomorphic morphological variants carry significantly worse prognosis (median OS 1–2 years) and mandate CNS prophylaxis and more intensive regimens.
For transplant-eligible patients, R-DHAP ×3 followed by autologous stem-cell transplant (ASCT) with rituximab maintenance is the standard-of-care consolidation approach.
For transplant-ineligible (elderly/unfit) patients, bendamustine-rituximab (BR) or R-CHOP/R-CVP followed by rituximab maintenance is preferred.
Ibrutinib (Imbruvica®), a BTK inhibitor, is PBS Authority Required in Australia for relapsed/refractory MCL after ≥1 prior therapy; it has transformed salvage outcomes.
Rituximab maintenance (every 2 months for 3 years) after induction improves progression-free survival and is standard for all fit patients.
MIPI (MCL International Prognostic Index) and MIPI-c (combined with Ki-67) stratify risk and guide treatment intensity, including consideration of early ASCT or novel agents.
CNS prophylaxis with intrathecal methotrexate or high-dose systemic methotrexate is recommended for blastoid variant, elevated LDH with Ki-67 >30 %, or CNS-IPI ≥4.
Aboriginal and Torres Strait Islander peoples may face barriers to timely specialist referral and access to SCT or novel agents; equitable pathways should be proactively established.
Treatment must be delivered in a multidisciplinary haematology setting; refer all patients to an accredited haematologist and consider clinical trial enrolment at every stage.

Introduction & Australian Epidemiology

Mantle cell lymphoma (MCL) is an uncommon but clinically significant B-cell non-Hodgkin lymphoma (NHL) that represents approximately 3–10 % of all NHL diagnoses. It is defined by a characteristic chromosomal translocation, t(11;14)(q13;q32), which juxtaposes the CCND1 (cyclin D1) gene under the immunoglobulin heavy-chain enhancer, resulting in constitutive cyclin D1 overexpression and dysregulated cell-cycle progression through the G1/S checkpoint.

In Australia, the estimated age-standardised incidence is 0.7–1.0 per 100 000 person-years. There were approximately 400–500 new diagnoses nationally in recent Cancer Australia data. MCL shows a striking male predominance (male:female ratio ~3:1) and a median age at diagnosis of 65–70 years. The disease has a heterogeneous clinical course: although historically considered uniformly aggressive, a subset of patients with non-nodal leukaemic MCL, SOX11-negative disease, and low Ki-67 proliferative index may follow an indolent course lasting years before requiring treatment.

Despite advances in therapy—particularly the introduction of Bruton tyrosine kinase (BTK) inhibitors such as ibrutinib—MCL remains incurable for the majority of patients, with median overall survival approximately 5–7 years in the modern era. Ongoing clinical trials investigating chimeric antigen receptor T-cell (CAR-T) therapy, bispecific antibodies, and next-generation BTK inhibitors offer hope for further improvement. This guideline provides an evidence-based overview of MCL pathogenesis, diagnosis, staging, and management in the Australian context, with attention to PBS-listed agents, MBS-funded investigations, and equity considerations for Aboriginal and Torres Strait Islander peoples.

Pathogenesis (Cyclin D1, t(11;14))

The t(11;14)(q13;q32) Translocation

The defining molecular event in MCL is the balanced chromosomal translocation t(11;14)(q13;q32). This rearrangement places the CCND1 gene on chromosome 11q13 under the control of the immunoglobulin heavy-chain (IGH) enhancer on chromosome 14q32, resulting in constitutive overexpression of cyclin D1 protein. This translocation is detectable by fluorescence in situ hybridisation (FISH) in >95 % of MCL cases and is considered the hallmark genetic abnormality.

Cyclin D1 and Cell-Cycle Dysregulation

Cyclin D1 is a regulatory subunit of cyclin-dependent kinases CDK4 and CDK6. Overexpression of cyclin D1 promotes phosphorylation of the retinoblastoma (Rb) protein, releasing E2F transcription factors and driving uncontrolled G1-to-S phase transition. This bypasses normal cell-cycle checkpoints, facilitating unrestrained proliferation of the malignant B-cell clone. Additional cooperating mutations in DNA damage response pathways (e.g., TP53, ATM) and cell survival pathways (NOTCH1, NF-κB) further contribute to disease aggressiveness and treatment resistance.

SOX11 and Subtypes

SOX11 (SRY-box transcription factor 11) is expressed in approximately 90 % of conventional MCL. SOX11-positive tumours typically follow an aggressive clinical course with nodal presentation. Conversely, SOX11-negative MCL, which often presents with peripheral blood involvement (leukaemic non-nodal MCL), bone marrow infiltration, and splenomegaly without significant lymphadenopathy, may pursue an indolent course for years. SOX11-negative cases frequently harbour fewer additional genetic aberrations and have a more favourable prognosis if monitored with a watch-and-wait approach.

Key Additional Genetic Alterations

Gene / Alteration	Frequency in MCL	Functional Consequence
t(11;14) / CCND1	>95 %	Cyclin D1 overexpression; cell-cycle drive
TP53 mutation / del(17p)	15–30 %	Loss of tumour suppressor; chemoresistance; worst prognosis
ATM mutation / del(11q)	40–75 %	Impaired DNA damage response; genomic instability
NOTCH1 mutation	10–15 %	Constitutive NOTCH activation; poorer outcome
CDKN2A loss	20–40 %	Loss of p16; enhanced CDK4/6 activity
Complex karyotype	50–70 %	Genomic instability; associated with blastoid variant

⚠️

Clinical implication: Patients with TP53 mutation or del(17p) have markedly inferior responses to conventional chemo-immunotherapy (R-CHOP, R-DHAP) and ASCT. These patients should be prioritised for BTK inhibitor-based therapy, CAR-T clinical trials, or allogeneic SCT where feasible.

Clinical Features & Staging

Clinical Presentation

MCL most commonly presents in men aged >60 years with advanced-stage disease. Key presenting features include:

Generalised lymphadenopathy — cervical, axillary, inguinal; often painless and progressive.
B symptoms — fevers, night sweats, unintentional weight loss >10 % over 6 months; present in 30–50 %.
Splenomegaly — often massive; more prominent in leukaemic non-nodal variant.
Gastrointestinal involvement — lymphomatous polyposis of the bowel is a recognised presentation; upper and lower GI endoscopy is recommended at staging even if asymptomatic.
Bone marrow infiltration — present in >70 % at diagnosis.
Peripheral blood involvement — circulating lymphoma cells seen in 20–30 %; higher in blastoid and leukaemic variants.
CNS involvement — rare at presentation (<5 %) but seen in blastoid variant and relapsed disease; symptoms include headache, cranial nerve palsies, altered consciousness.

Morphological Variants

Variant	Frequency	Features	Prognosis
Classical (small-to-medium cells)	~75 %	Irregular nuclear contours, dispersed chromatin	Intermediate
Blastoid	~15 %	Larger cells, fine chromatin, high mitotic rate, resembles lymphoblastic lymphoma	Very poor (median OS 1–2 years)
Pleomorphic	~10 %	Marked variation in cell size and shape	Poor
Leukaemic non-nodal	~5 %	Peripheral blood/bone marrow predominant; SOX11-negative; splenomegaly	Indolent course possible

Ann Arbor Staging (Lugano Classification)

MCL is almost always Stage III or IV at presentation. The Ann Arbor system (modified by the 2014 Lugano Classification) is used:

Stage	Distribution	Approximate % at Diagnosis
I	Single lymph node region	<5 %
II	≥2 lymph node regions, same side of diaphragm	5–10 %
III	Lymph node regions on both sides of diaphragm	10–15 %
IV	Diffuse extranodal involvement (bone marrow, liver, GI)	~75 %

Prognostic Scoring — MIPI and MIPI-c

The MCL International Prognostic Index (MIPI) uses four variables—age, ECOG performance status, LDH/ULN ratio, and WBC count—to classify patients into low-, intermediate-, and high-risk groups. The MIPI-c incorporates Ki-67 proliferative index for refined stratification:

Low Risk

MIPI 0–3 (MIPI-c low)

Median OS not reached at 5 years in many series. Younger, fitter patients.

Setting: Consider intensive induction + ASCT

Intermediate Risk

MIPI 4–5 (MIPI-c intermediate)

Median OS 5–7 years. Moderate disease burden.

Setting: Chemo-immunotherapy ± ASCT per fitness

High Risk

MIPI 6–11 (MIPI-c high)

Median OS 2–3 years. High WBC, poor PS, high Ki-67. Consider novel agents upfront.

Setting: BTK inhibitor-based therapy or clinical trial preferred

Investigations (SOX11, Cyclin D1 IHC)

Histopathology & Immunohistochemistry

Diagnosis of MCL requires an excisional lymph node biopsy reviewed by an experienced haematopathologist. Core-needle biopsy may be acceptable if excisional biopsy is not feasible, but diagnostic accuracy is reduced. The following immunohistochemical (IHC) panel is essential:

Essential

Cyclin D1 IHC

Nuclear staining positive in >95 % of MCL. This is the single most important IHC marker. Negative cyclin D1 does not exclude MCL (rare cyclin D1-negative, SOX11-positive cases exist).

Essential

SOX11 IHC

Nuclear staining positive in ~90 % of conventional MCL. SOX11 negativity suggests leukaemic non-nodal variant with possible indolent course. Critical for distinguishing MCL from CLL/SLL and other CD5+ lymphomas.

Essential

CD20, CD5, CD19, CD79a

Classic MCL phenotype: CD20+, CD5+, CD19+, CD79a+. CD23 is typically negative or weakly positive (helps distinguish from CLL/SLL which is CD23+). FMC7 positive.

Essential

Ki-67 (MIB-1) proliferative index

Percentage of cells staining for Ki-67 is critical for MIPI-c risk stratification and prognosis. Ki-67 ≥30 % defines high proliferation; ≥50 % (especially in blastoid) is very high risk.

Available

TP53 IHC

Overexpression (strong nuclear staining in >50 % of cells) correlates with TP53 mutation and del(17p). Emerging as a standard prognostic marker in MCL.

Cytogenetics & FISH

Essential

FISH for t(11;14) / CCND1-IGH rearrangement

Confirms the diagnostic translocation. MBS item 73309 (FISH, single probe) or 73316 (dual-fusion probe) — Medicare rebate available. If cyclin D1 IHC is unequivocally positive, FISH is confirmatory but not strictly required for diagnosis.

Available

FISH for del(17p)/TP53, del(11q)/ATM, del(13q), +12

Prognostically important; should be performed at diagnosis to identify high-risk patients. MBS item 73309 or 73316 depending on probe set.

Available

Conventional karyotyping (G-banding)

Useful for identifying complex karyotype (≥5 abnormalities), which is associated with blastoid morphology and inferior survival. Not always performed but recommended if feasible.

Molecular Studies

Referral

Next-generation sequencing (NGS) panel

Targeted NGS panels (e.g., TP53, ATM, NOTCH1, NOTCH2, CCND1, CDKN2A) are increasingly used in major Australian centres. Not yet MBS-listed; cost typically 0–1000. Refer to haematopathology service for availability.

Referral

Gene expression profiling (Lymph2Cx / Lymph3Cx)

NanoString-based assays can classify lymphoma subtypes from FFPE tissue. Available at selected reference laboratories. Useful in diagnostically challenging cases.

Baseline Staging Investigations

CT chest/abdomen/pelvis with IV contrast (MBS item 56809) — standard anatomical staging.
PET-CT (MBS item 61651) — recommended by Lugano Classification for FDG-avid lymphomas including MCL. Baseline SUVmax and Deauville score at interim scan inform response assessment.
Bone marrow aspirate & trephine biopsy — confirm marrow involvement; morphology, IHC (cyclin D1, CD20, CD5), flow cytometry, and FISH on marrow sample.
Upper & lower GI endoscopy — recommended for all patients given ~30 % GI involvement; lymphomatous polyposis may be present despite absence of GI symptoms.
Laboratory panel: FBC, LDH, β2-microglobulin, albumin, LFTs, UEC, urate, CMV/EBV serology (pre-therapy).
Echocardiogram or MUGA scan — baseline cardiac function prior to anthracycline-containing regimens.
CNS assessment — MRI brain + lumbar puncture with CSF cytology/flow cytometry for blastoid variant, elevated LDH with Ki-67 >30 %, or CNS-IPI ≥4.

ℹ️

Australian practice point: Flow cytometry on peripheral blood and bone marrow is MBS-listed (item 69341 — restricted to haematologist referral) and provides rapid identification of clonal B-cell population with characteristic CD5+/CD23−/CD20+ phenotype, supporting a working diagnosis while histopathological and FISH results are pending.

Management (R-CHOP, Ibrutinib, SCT)

Treatment Overview

Management of MCL is guided by patient age, fitness (assessed by comprehensive geriatric assessment or transplant eligibility criteria), morphological variant, MIPI/MIPI-c risk score, and TP53 status. The two broad treatment pathways are transplant-eligible (intensive) and transplant-ineligible (non-intensive).

⚠️

Watch-and-wait consideration: A small subset of patients with asymptomatic, SOX11-negative, non-nodal leukaemic MCL with low Ki-67 (<10 %) and no high-risk genetic features may be observed with active surveillance. This approach should only be undertaken under the guidance of an experienced haematologist and is not appropriate for conventional nodal MCL.

Transplant-Eligible Patients (Age ≤65–70, Fit)

The Nordic MCL2 protocol or R-DHAP-based induction followed by ASCT is the standard-of-care for transplant-eligible patients:

1

Induction: R-DHAP × 3 cycles

Rituximab 375 mg/m² IV D1 + Dexamethasone 40 mg PO/IV D1–4 + Cisplatin 100 mg/m² IV continuous infusion over 24 h D1 + Cytarabine 2 g/m² IV q12h × 2 doses D2. Each cycle every 21 days. Interim PET-CT after 2–3 cycles.

2

Stem-cell mobilisation & collection

G-CSF ± plerixafor for CD34+ stem-cell harvest. Target ≥2 × 10⁶ CD34+ cells/kg.

3

Conditioning & ASCT

High-dose BEAM conditioning (Carmustine, Etoposide, Cytarabine, Melphalan) followed by autologous stem-cell infusion.

4

Rituximab maintenance

Rituximab 375 mg/m² IV every 2 months for 3 years (total ~18 doses). Commences 2–3 months post-ASCT.

Alternative induction for transplant-eligible patients: Nordic MCL3 protocol — R-maxi-CHOP alternating with R-HD-cytarabine × 6 cycles. Some Australian centres prefer this regimen when cisplatin is contraindicated.

Transplant-Ineligible Patients (Elderly or Comorbid)

1

Induction: Bendamustine-Rituximab (BR)

Bendamustine 90 mg/m² IV D1–2 + Rituximab 375 mg/m² IV D1. Every 28 days × 6 cycles. Preferred first-line for elderly/favourable-risk patients.

2

Alternative: R-CHOP × 6

Rituximab 375 mg/m² IV D1 + Cyclophosphamide 750 mg/m² IV D1 + Vincristine 1.4 mg/m² IV D1 (capped at 2 mg) + Doxorubicin 50 mg/m² IV D1 + Prednisone 100 mg PO D1–5. Every 21 days × 6 cycles.

3

Rituximab maintenance

Rituximab 375 mg/m² IV every 2 months for 3 years. Commences 2 months after completion of induction.

Key Drug Cards

💊

Rituximab

MabThera® · Riximyo® · Biosimilars · Anti-CD20 monoclonal antibody

Adult dose 375 mg/m² IV on D1 of each cycle; maintenance 375 mg/m² IV every 2 months for 3 years

Paediatric dose 375 mg/m² IV (limited paediatric MCL data)

Renal adjustment No adjustment required

Hepatic adjustment No formal adjustment; use with caution in severe hepatic impairment

PBS status ✔ PBS General Benefit

💊

Ibrutinib

Imbruvica® · BTK inhibitor

Adult dose 560 mg PO once daily; continue until disease progression or unacceptable toxicity

Renal adjustment No dose adjustment; avoid in severe renal impairment (CrCl <25 mL/min) due to limited data

Hepatic adjustment Mild (Child-Pugh A): 140 mg daily; Moderate (Child-Pugh B): 70 mg daily; Severe (Child-Pugh C): avoid

Key interactions CYP3A4 inhibitor/substrate — avoid strong CYP3A4 inhibitors (ketoconazole, clarithromycin) and inducers (rifampicin, carbamazepine)

PBS status ✔ PBS Authority Required — Relapsed/refractory MCL after ≥1 prior therapy

💊

Bendamustine

Ribomustin® · Bendamustine Hospira · Alkylating agent

Adult dose 90 mg/m² IV over 60 min D1–2; every 28 days × 6 cycles (BR regimen)

Renal adjustment CrCl <40 mL/min: avoid or reduce to 50 mg/m² — limited data

Hepatic adjustment AST/ALT 2.5–10 × ULN: reduce to 50 mg/m²; >10 × ULN: avoid

PBS status ✔ PBS General Benefit

💊

Cytarabine (High-dose)

Cytosar® · Cytarabine Hospira · Antimetabolite

Adult dose (R-DHAP) 2 g/m² IV over 3 h q12h × 2 doses (D2) — induction; 3 g/m² IV q12h × 4 doses in some CNS prophylaxis protocols

Renal adjustment No formal dose reduction; monitor for toxicity in renal impairment

Hepatic adjustment Consider dose reduction in significant hepatic dysfunction; risk of increased neurotoxicity

PBS status ✔ PBS General Benefit

💊

Acalabrutinib

Calquence® · Second-generation BTK inhibitor

Adult dose 100 mg PO BD; continue until progression or unacceptable toxicity

Renal adjustment No dose adjustment; avoid in severe renal impairment (limited data)

Hepatic adjustment Mild-moderate: 100 mg once daily; Severe: avoid

PBS status ⚠ PBS Authority Required — CLL (listed); MCL — not currently PBS-listed in Australia as of 2024. Access via compassionate use or clinical trial.

Relapsed / Refractory MCL

Relapsed MCL carries a poor prognosis with conventional salvage chemotherapy. BTK inhibitors have transformed outcomes:

Ibrutinib monotherapy — first-choice salvage in R/R MCL; PBS Authority Required (≥1 prior line). ORR ~68 %, median PFS ~14 months.
Acalabrutinib — second-generation BTK inhibitor with improved selectivity; similar efficacy, potentially fewer cardiac events. Not PBS-listed for MCL currently.
Zanubrutinib — another next-generation BTK inhibitor; emerging data in MCL. Not PBS-listed for MCL.
Lenalidomide + Rituximab (R²) — option for patients intolerant to BTK inhibitors. Lenalidomide is PBS-listed for myeloma; off-label use in MCL requires private script or authority negotiation.
CAR-T cell therapy (brexucabtagene autoleucel, Tecartus®) — TGA-approved for R/R MCL after ≥2 prior lines including a BTK inhibitor. Available at selected Australian centres (e.g., Peter MacCallum, RPA, Royal Adelaide). Significant toxicity risk (CRS, ICANS) — specialised centre management required.
Clinical trials — always consider enrolment for R/R MCL; bispecific antibodies (glofitamab, epcoritamab), ADCs, and combination BTK inhibitor trials are ongoing in Australia.

CNS Prophylaxis

🚨

Blastoid variant mandates CNS prophylaxis. Intrathecal methotrexate 12–15 mg per dose (4–8 doses during induction) is the minimum. Consider systemic high-dose methotrexate (3–3.5 g/m²) for highest-risk patients. CNS-IPI ≥4 also warrants prophylaxis.

Intrathecal methotrexate dose: 12–15 mg (adjust for body weight if <50 kg). Administer via lumbar puncture at each induction cycle. For patients receiving R-DHAP, intrathecal cytarabine 50 mg is an alternative. High-dose systemic methotrexate (3–3.5 g/m² IV) achieves therapeutic CSF levels and is preferred when blastoid morphology, high Ki-67, or elevated LDH with CNS-IPI ≥4.

Monitoring During & After Treatment

Response assessment: PET-CT (Deauville criteria) at interim (after 2–3 cycles) and end-of-treatment. CT alone if PET unavailable.
Minimal residual disease (MRD): Not yet standard-of-care but increasingly used. Sensitive PCR or NGS-based assays detect t(11;14) in blood/bone marrow. MRD negativity post-ASCT correlates with longer PFS. Consider at selected centres.
Ongoing surveillance: Clinical review every 3 months for 2 years, then every 6 months for 3 years, then annually. CT every 6 months for 2 years, then annually for 3 years.
Ibrutinib monitoring: FBC every 2 weeks for first 3 months, then monthly. Monitor for atrial fibrillation (ECG at baseline and periodically), bleeding, hypertension, arthralgia, infection risk. Manage drug interactions with pharmacist input.
Rituximab maintenance: Monitor immunoglobulin levels; IV immunoglobulin replacement if IgG <4 g/L with recurrent infections.

Special Populations

🤰 Pregnancy

MCL in pregnancy is exceptionally rare.

Rituximab: crosses placenta in 2nd/3rd trimester; risk of neonatal B-cell depletion and prolonged hypogammaglobulinaemia. Avoid if possible in first trimester. Anthracyclines (doxorubicin) may be considered in 2nd/3rd trimester under specialist guidance. Ibrutinib is contraindicated (Category D). Multidisciplinary obstetric-haematology team essential.

👶 Paediatrics

MCL is extremely rare in children and adolescents.

Cases in paediatric patients (typically 10–17 years) may present with blastoid morphology and aggressive disease. Management is extrapolated from adult protocols. Refer to a paediatric haematology-oncology centre (e.g., Children's Hospital at Westmead, RCH Melbourne). Paediatric-specific dosing for rituximab, cytarabine, and BTK inhibitors should be guided by paediatric pharmacology expertise.

👴 Elderly

Median age 65–70; majority transplant-ineligible.

Use comprehensive geriatric assessment (CGA) to guide fitness for therapy. BR regimen is generally preferred over R-CHOP in elderly patients (superior PFS, less toxicity in the BRIGHT and STiL trials). Rituximab maintenance is well tolerated in elderly. Dose-reduce vincristine (cap at 2 mg) and consider omitting if peripheral neuropathy present. Ibrutinib is highly active in elderly R/R patients and is generally well tolerated.

🫘 Renal Impairment

Dose adjust bendamustine (CrCl <40 mL/min: reduce to 50 mg/m²).

Cisplatin is nephrotoxic — avoid or substitute carboplatin in R-DHAP if CrCl <60 mL/min. High-dose cytarabine: no formal adjustment but monitor for cerebellar toxicity. Ibrutinib: no dose change but avoid if CrCl <25 mL/min (limited data). Rituximab: no adjustment. Ensure adequate hydration during chemotherapy infusions.

🫁 Hepatic Impairment

Ibrutinib dose reduction in hepatic impairment (see drug card above).

Bendamustine: reduce to 50 mg/m² if AST/ALT 2.5–10 × ULN; avoid if >10 × ULN. Vincristine: avoid in severe hepatic impairment (cholestatic jaundice). Rituximab: no dose change but increased infusion reactions reported. Monitor LFTs closely throughout treatment.

🛡️ Immunocompromised

MCL patients are inherently immunosuppressed due to disease and therapy.

Rituximab causes prolonged B-cell depletion (6–9 months post-treatment). Check HBV status (HBsAg, anti-HBc, HBV DNA) before rituximab — antiviral prophylaxis (entecavir) for HBsAg+ or anti-HBc+ patients. Pneumocystis prophylaxis (TMP-SMX) during intensive chemotherapy. Monitor immunoglobulin levels; consider IVIg if recurrent infections. Avoid live vaccines during and for 6 months after rituximab.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Although specific incidence data for MCL in Aboriginal and Torres Strait Islander peoples are limited, NHL as a group is diagnosed at a younger age and at a more advanced stage in Indigenous Australians. Systemic barriers contribute to delayed diagnosis and reduced access to optimal therapy.

Remote access to specialist care

Many Aboriginal and Torres Strait Islander patients reside in regional or remote areas without local haematology services. Specialist referral may require travel of hundreds of kilometres to metropolitan centres. Telehealth haematology consultations (MBS items 91822, 91823) can facilitate initial assessment and ongoing monitoring. Proactive engagement with Aboriginal Health Workers and AMS (Aboriginal Medical Services) is essential for care coordination.

Access to ASCT and novel agents

Autologous SCT and CAR-T therapy are available only at major tertiary centres in capital cities. Aboriginal and Torres Strait Islander patients may face additional barriers including relocation costs, separation from family/community, and cultural safety concerns. State/territory Patient-Assisted Travel Schemes (PATS) and hospital social work services should be engaged early. Ibrutinib (PBS Authority Required) is accessible nationally via community pharmacy once approved.

Cancer staging at diagnosis

Indigenous Australians with NHL are more likely to present at Stage IV and with B symptoms. Earlier community awareness and streamlined GP-to-specialist referral pathways through Aboriginal Community Controlled Health Organisations (ACCHOs) can reduce diagnostic delay.

Comorbidity burden

Higher prevalence of diabetes, chronic kidney disease, cardiovascular disease, and hepatitis B in Aboriginal and Torres Strait Islander communities impacts treatment tolerability. Baseline assessments (renal function, hepatic serology including HBV, echocardiography) are critical before commencing chemo-immunotherapy. Dose modifications may be more frequently required.

Cultural safety in cancer care

Acknowledge the diversity of Aboriginal and Torres Strait Islander cultures. Engage Indigenous patient navigators or liaison officers where available. Respect kinship obligations and cultural practices around illness and death. Provide information in plain English and, where possible, in locally relevant language. Ensure smoking cessation support is culturally appropriate.

Clinical trial representation

Aboriginal and Torres Strait Islander peoples are significantly under-represented in haematological cancer clinical trials. Actively screen for trial eligibility and address barriers to enrolment (travel, mistrust, language). Support trial designs that include remote monitoring components.

📚 References

1. Dreyling M, Campo E, Hermine O, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv62–iv71.
2. Cheah CY, Seymour JF, Wang ML. Mantle cell lymphoma. J Clin Oncol. 2016;34(11):1256–1269.
3. Hermine O, Hoster E, Walewski J, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016;388(10044):565–575.
4. Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507–516.
5. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203–1210.
6. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111(2):558–565.
7. Hoster E, Rosenwald A, Berger F, et al. Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European Mantle Cell Lymphoma Network. J Clin Oncol. 2016;34(12):1386–1394.
8. Wang ML, Shah NN, Jurczak W, et al. Efficacy of brexucabtagene autoleucel (KTE-X19) in patients with relapsed/refractory mantle cell lymphoma in the ZUMA-2 trial. J Clin Oncol. 2021;39(suppl 15):7544.
9. Australian Institute of Health and Welfare (AIHW). Cancer data in Australia. Canberra: AIHW; 2024. Available from: https://www.aihw.gov.au/reports/cancer/cancer-data-in-australia
10. Cancer Australia. Non-Hodgkin lymphoma — national cancer control indicators. Surry Hills, NSW: Cancer Australia; 2023.
11. Chan KL, Blombery P, Westerman D, et al. Genomic landscape and clinical outcomes of mantle cell lymphoma in the era of targeted therapy: an Australian multi-centre experience. Intern Med J. 2022;52(suppl 2):S45.
12. National Health and Medical Research Council (NHMRC). Ethical conduct in research with Aboriginal and Torres Strait Islander Peoples and communities: guidelines for researchers and stakeholders. Canberra: NHMRC; 2018.
13. Services Australia. Medicare Benefits Schedule (MBS). Canberra: Australian Government. Available from: https://www.mbsonline.gov.au
14. Australian Government Department of Health. Pharmaceutical Benefits Scheme (PBS). Available from: https://www.pbs.gov.au